Wellington Biomedical Innovation Master Investors (Cayman) II L.P. - Nov 14, 2023 Form 4 Insider Report for CARGO Therapeutics, Inc. (CRGX)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Peter McIsaac, Title: Authorized Person
Stock symbol
CRGX
Transactions as of
Nov 14, 2023
Transactions value $
$0
Form type
4
Date filed
11/16/2023, 04:19 PM
Previous filing
Sep 19, 2023
Next filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRGX Common Stock Conversion of derivative security +737K 737K Nov 14, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRGX Series A-1 Preferred Stock Conversion of derivative security $0 -10M -100% $0.00* 0 Nov 14, 2023 Common Stock 737K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) II L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date.